Volume 13, Number 7—July 2007
Research
Antimicrobial Drugs and Community-acquired Methicillin-Resistant Staphylococcus aureus, United Kingdom
Verena Schneider-Lindner*†, J. A. Delaney*†, Sandra Dial†‡, Andre Dascal‡, and Samy Suissa*†
Table 2
Risk for infection with community-acquired methicillin-resistant Staphylococcus aureus (MRSA)*
| No. prescriptions of antimicrobial drugs | Case-patients (N = 1,981), no. (%) | Control-patients (N = 19,779), no. (%) | Crude OR | Adjusted OR† | 95% CI |
|---|---|---|---|---|---|
| 0 (reference) | 770 (38.9) | 12,821 (64.8) | 1 | 1 | |
| >1 | 1,211 (61.1) | 6,958 (35.2) | 2.98 | 2.61 | 2.36–2.89 |
| 1 | 328 (16.6) | 3,306 (16.7) | 1.69 | 1.57 | 1.36–1.80 |
| 2 or 3 | 373 (18.8) | 2,389 (12.1) | 2.73 | 2.46 | 2.15–2.83 |
| >4 | 510 (25.7) | 1,263 (6.4) | 7.27 | 6.24 | 5.43–7.17 |
*For persons prescribed <1 antimicrobial drug in the 30–365 days before their index date, relative to risk for MRSA infection in persons with no prescriptions during the same period. Data from General Practice Research Database, United Kingdom, 2000–2004. OR, odds ratio; CI, confidence interval.
†Adjusted for all variables in Table 1.
Page created: June 21, 2010
Page updated: June 21, 2010
Page reviewed: June 21, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.